protocolSection identificationModule nctId: NCT06327880, orgStudyIdInfo id: C4151006, secondaryIdInfos id: 2023-509339-17-00, type: REGISTRY, domain: CTIS (EU), briefTitle: A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-13, primaryCompletionDateStruct date: 2024-07-02, completionDateStruct date: 2024-07-02, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Pfizer, class: INDUSTRY, descriptionModule briefSummary: The purpose of this clinical study is to learn about the safety and effects of the study medicine (PF-07054894) in healthy Japanese participants.The study is seeking the following participants:* Male or female Japanese participants aged 18 years or older. The participants should be healthy after going through some medical tests.* Have a Body Mass Index (BMI) of 16 to 32 kilogram per meter squared; and a total body weight of more than 45 kilograms (100 pounds).* Are willing and able to follow all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.In research, the participants in clinical studies are assigned by chance to separate groups that are given different treatments. Hence participants will be by chance assigned to receive either PF-07054894 or a harmless treatment that has no medical effect (placebo). Both these will be taken by mouth for 14 days. The total duration of the study is about 11 weeks, with a follow-up via telephone about 6 weeks after first treatment., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 6, type: ESTIMATED, armsInterventionsModule interventions name: PF-07054894 or placebo, outcomesModule primaryOutcomes measure: Number of participants with adverse events (AE) or serious adverse events (SAE), primaryOutcomes measure: Number of participants with clinically meaningful change from baseline in laboratory tests results, primaryOutcomes measure: Number of participants with clinically meaningful change from baseline in vital signs, primaryOutcomes measure: Number of participants with clinically meaningful change from baseline in electrocardiogram (ECG) parameters, primaryOutcomes measure: Maximal plasma concentration (Cmax), primaryOutcomes measure: Time to Maximum Plasma Concentration (Tmax), primaryOutcomes measure: Area Under the Plasma Concentration-Time Profile From Time Zero (AUCτ) To End of Dosing Interval (AUCt), primaryOutcomes measure: Half-life of PF-07054894, secondaryOutcomes measure: Observed Accumulation Ratio (Rac), secondaryOutcomes measure: Observed Accumulation Ratio Based on Cmax (Rac,Cmax), secondaryOutcomes measure: Trough plasma concentrations (Ctrough), secondaryOutcomes measure: Apparent Volume of Distribution (Vz/F) as data permits, secondaryOutcomes measure: Apparent Oral Clearance (CL/F), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pfizer Clinical Research Unit - Brussels, city: Brussels, state: Bruxelles-capitale, Région DE, zip: B-1070, country: Belgium, geoPoint lat: 50.85045, lon: 4.34878, hasResults: False